The FDA on February 5, 2021 approved BREYANZI® for the treatment of adult patients with Relapsed or Refractory (R/R) Large B-Cell Lymphoma after two or more lines of systemic therapy, including Diffuse Large B-Cell Lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), High-Grade B-Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma, and Follicular Lymphoma Grade 3B. BREYANZI® is a product of Juno Therapeutics, Inc.
Bottom Ad
Advertisement
Subscribe
